Hodgkin's lymphoma Posts on Medivizor
Navigation Menu

Hodgkin’s lymphoma Posts on Medivizor

Evaluating GVDex chemotherapy for patients with recurrent or persistent Hodgkin’s lymphoma

Posted by on Aug 19, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined if GVDex is as effective and safe as GVDoxil for treating Hodgkin's lymphoma (HL) that has come back or stopped responding to treatment. The authors found that GVDex was as effective as GVDoxil, with fewer side effects. Some background For most patients with HL, primary therapy is highly effective....

Read More

How common is blood clotting in patients with Hodgkin’s lymphoma?

Posted by on Aug 8, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated how often patients Hodgkin’s lymphoma (HL) experienced blood clots and what factors increased the risk of blood clots.  The authors found that patients with advanced HL were more likely to develop blood clots, particularly during chemotherapy, and that age, smoking status, and treatment frequency increased...

Read More

Does the modification of chemotherapy reduce heart disease side effects in patients with Hodgkin lymphoma?

Posted by on Aug 4, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined if a modified version of doxorubicin (Adriamycin) in ABVD chemotherapy was safe and effective in patients with Hodgkin’s lymphoma who had heart disease. This study found that this regimen was safer and just as effective as conventional ABVD. Some background Hodgkin’s lymphoma (HL) is a cancer of white...

Read More

Searching for participants with high risk relapsed or unresponsive Hodgkin lymphoma to try a treatment combination.

Posted by on Jul 29, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study will investigate the effects of nivolumab (Opdivo) and brentuximab vedotin (Adcetris) after stem cell transplant in patients with high risk relapsed or refractory Hodgkin lymphoma (RRHL). The main outcome that will be measured is progression-free survival. This trial is recruiting in multiple locations in the United States. The...

Read More

Looking for patients with relapsed or unresponsive classical Hodgkin lymphoma to test a new treatment combination

Posted by on Jul 21, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study is evaluating how well a new chemoimmunotherapy regimen works in treating patients with classical Hodgkin’s lymphoma (cHL) that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer after treatment. This study...

Read More

First-line treatment options for patients with Hodgkin’s lymphoma

Posted by on Jul 18, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This article reviewed different options for first-line treatment for Hodgkin lymphoma (HL). Some background Treatment for patients with HL has become more individualized. Treatment strategies have been adapted to disease risk, and how well patients respond to initial treatment. The goal of these approaches is to reduce side effects...

Read More

Evaluating pembrolizumab in Hodgkin lymphoma after transplantation

Posted by on Jul 18, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study looked at the safety and effectiveness of pembrolizumab (Keytruda) in the treatment of patients with relapsed or unresponsive Hodgkin lymphoma after stem cell transplant. Researchers found that pembrolizumab was a safe and effective treatment when used in this way. Some background Hodgkin lymphoma is a cancer of the immune...

Read More

Using IL2 levels to predict outcomes for patients with classical Hodgkin lymphoma

Posted by on Jul 14, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated whether interleukin-2 receptor levels in the blood influenced the outcomes of patients with classical Hodgkin’s lymphoma (cHL). This study concluded that this can be a useful tool for predicting prognosis for these patients. Some background Chemotherapy remains the standard first-line treatment for HL. One...

Read More

Treatment options for patients with recurrent or non-responsive Hodgkin lymphoma

Posted by on Jul 9, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This article reviewed current treatment options for patients with Hodgkin lymphoma (HL) that has come back (relapsed) or stopped responding to treatment (refractory). Some background Chemotherapy remains the standard first-line treatment for HL. One of the most commonly used regimens is ABVD (doxorubicin, bleomycin, vinblastine,...

Read More